Analysis of Shanghai Hile Bio-Technology Co., Ltd. completed the acquisition of an additional 41% stake in Shaanxi Reshine Biotech Co. Ltd. from Maylion Management Limited. - aVenture Research
MarketScreener
Shanghai Hile Bio-Technology Co., Ltd. completed the acquisition of an additional 41% stake in Shaanxi Reshine Biotech Co. Ltd. from Maylion Management Limited.
Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) agreed to acquire an additional 41% stake in Shaanxi Reshine Biotech Co. Ltd. from Maylion Management Limited for approximately CNY 400 million on November 28, 2025. A cash consideration of CNY 399.3 million will be paid by Shanghai Hile Bio-Technology Co., Ltd. As part of consideration, CNY 399.3 million is paid towards common equity of Shaanxi Reshine Biotech Co. Ltd. Upon completion, Shanghai Hile Bio-Technology Co., Ltd. will own 96% stake